Logo

Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease

Share this
Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease

Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease

Shots:

  • Teva to get an exclusive license globally to develop, manufacture & commercialize anle138b &sery433. Additionally, both companies will jointly develop the products for MSA & PD  based on early-stage clinical studies & will investigate additional indications based on clinical outcomes
  • The P-I study of anle138b demonstrated a favorable benefit-risk profile at all doses while achieving higher plasma levels than those required for full therapeutic efficacy in animal models
  • Modag's Anle138b has been initially developed for MSA & PD & is designed to facilitate other ND disorders such as AD. Anle138b is currently being evaluated in a P-Ib clinical trial for the patient with PD

 ­ | Ref: Teva | Image: Biospace

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions